Company intelligence / Profile preview

1315 Capital

Philadelphia, Pennsylvania, United States

Ownership: Private
Employees: ~14
Development stage: Other

Overview

1315 Capital is a healthcare-focused private equity firm that provides growth capital, typically $10M-$60M per investment, to commercial-stage healthcare, medical technology, and specialty pharma and services firms. It manages over $1 billion in assets and operates with an 'operating team' model. As an investment firm, it does not develop drugs or have a therapeutic pipeline.

Industry: Investors

Partnerships

Experic (CDMO, biopharmaceutical manufacturing)Triple Ring Technologies (medical device and life sciences R&D co-development)Primrose Bio (manufacturing for nucleic acids/proteins for therapeutics)

Beyond the preview

Go deeper on 1315 Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1315 Capital.

Explore the full profile